Texas AG sues makers of Tylenol over hiding alleged links to autism
Paxton claimed Tylenol was deceptively marketed to pregnant women.
By Mary Kekatos and Will McDuffie
October 28, 2025, 6:56 AM
Texas Attorney General Ken Paxton sued the makers of Tylenol, Johnson & Johnson and Kenvue, claiming that they deceptively marketed the over-the-counter medication to pregnant women despite alleged links to autism and other disorders.
“Big Pharma betrayed America by profiting off of pain and pushing pills regardless of the risks," Paxton said in a statement on Tuesday. "These corporations lied for decades, knowingly endangering millions to line their pockets. ... By holding Big Pharma accountable for poisoning our people, we will help Make America Healthy Again.”
This is the first lawsuit from a state government since President Donald Trump claimed last month that Tylenol use during pregnancy is linked to an increased risk of autism, despite limited evidence to suggest an association.
Johnson & Johnson sold the drug for decades and its consumer health division spinoff, Kenvue Inc., has been selling the drug since 2023.
In a statement, Kenvue pushed back on the attorney general's claims, saying it is "deeply concerned by the perpetuation of misinformation on the safety of acetaminophen and the potential impact that could have on the health of American women and children."
"Acetaminophen is the safest pain reliever option for pregnant women as needed throughout their entire pregnancy. Without it, women face dangerous choices: suffer through conditions like fever that are potentially harmful to both mom and baby or use riskier alternatives. High fevers and pain are widely recognized as potential risks to a pregnancy if left untreated," the statement read. "We will defend ourselves against these baseless claims and respond per the legal process. We stand firmly with the global medical community that acknowledges the safety of acetaminophen and believe we will continue to be successful in litigation as these claims lack legal merit and scientific support."
This is a developing story. Please check back for updates.
